Characteristics and outcome of Prostate cancer patients with overall biopsy Gleason score 3+4=7 and highest Gleason score 3+4=7 or > 3+4=7

Prostate cancer heterogeneity and multifocality might result in different Gleason scores (GS) at individual biopsy cores. According to WHO/ISUP guidelines, the GS in each biopsy core should be recorded with optional reporting of overall GS for the entire case. We aimed to compare the clinicopathologic characteristics and outcome of men with overall biopsy GS 3+4=7 with highest GS 3+4=7 (HI=OV) to those with highest GS > 3+4=7 (HI>OV).

Prostate cancer biopsies from the European Randomized Study of Screening for Prostate Cancer (ERSPC) were revised according to WHO/ISUP 2014 guidelines (n=1031). In total 370 patients had overall GS 3+4=7, of whom 60 (16%) had at least one biopsy core with GS 4+3=7 or 4+4=8. Men with higher GS than 3+4 (HI>OV) in any of the cores had higher age, Prostate Specific Antigen (PSA) level, number of positive biopsies, percentage tumour involvement, percentage Gleason grade 4 and cribriform or intraductal growth (all P<.05) than those with GS 3+4=7 at highest (HI=OV). In multivariable Cox regression analysis including PSA, percentage positive biopsies and percentage tumour involvement, biochemical recurrence-free survival after radical prostatectomy (P=.52) or radiotherapy (P=.35) was not statistically different between both groups.

Among patients with overall GS 3+4=7, those with highest GS >3+4=7 had worse clinicopathologic features, but clinical outcome was not statistically significant. Therefore use of overall GS instead of highest GS for clinical decision-making is justified, potentially preventing overtreatment in prostate cancer patients. This article is protected by copyright. All rights reserved.

Histopathology. 2017 Nov 01 [Epub ahead of print]

Esther I Verhoef, Charlotte F Kweldam, Intan P Kümmerlin, Daan Nieboer, Chris H Bangma, Luca Incrocci, Theodorus H van der Kwast, Monique J Roobol, Geert J van Leenders

Department of Pathology, Erasmus Medical Centre Rotterdam, The Netherlands., Department of Public Health, Erasmus Medical Centre Rotterdam, The Netherlands., Department of Urology, Erasmus Medical Centre Rotterdam, The Netherlands., Department of Radiotherapy, Erasmus Medical Centre Rotterdam, The Netherlands., Laboratory Medicine Program, University Health Network, Toronto, Canada.